-a new purified hyaluronate sodium I.V. product for horses-
BELLEVILLE, ON, Dec. 4, 2012 /CNW/ - Bioniche Life Sciences Inc. (TSX:
BNC) (ASX: BNC), a research-based, technology-driven Canadian
biopharmaceutical company, today announced that it has launched a new
product for horses - NexHA™ - in Canada.
NexHA™ is a specialized formulation of purified hyaluronate sodium that can
be administered to horses by intravenous or intra-articular injection.
It is indicated in the treatment of joint dysfunction of the carpus or
fetlock in horses due to non-infectious synovitis associated with
equine osteoarthritis. Hyaluronate sodium acts as a replacement for
synovial fluid, the naturally occurring lubricant in articular joints.
Joint degeneration is associated with the loss of synovial fluid, and
the lack of its lubricant effects results in considerable pain and
inflammation for the horse.
The Company has been developing different formulations of sodium
hyaluronate for the equine markets in Canada, Australia and New Zealand
- sold as Enhance® - since 2001/02. Both Enhance® and NexHA™ are produced with a sodium hyaluronate solution that is obtained from a
selective fermentation source using a manufacturing process that is
free from thermal degrading effects and delivering high specificity.
"Lameness due to osteoarthritis is very common in the horse, whether
racing, sport or pleasure horse," said Mr. Andrew Grant, President,
Bioniche Animal Health (Global). "Bioniche has been a leading developer
of highly purified hyaluronate sodium technologies to address this
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery,
development, manufacturing, and marketing of proprietary and innovative
products for human and animal health markets worldwide. The
fully-integrated company employs more than 200 skilled personnel and
has three operating divisions: Human Health, Animal Health, and Food
Safety. The Company's primary goal is to develop and commercialize
products that advance human or animal health and increase shareholder
Bioniche Animal Health develops, manufactures and markets veterinary
biopharmaceutical products worldwide. In North America, it has
development, manufacturing and marketing facilities in Belleville,
Ontario, Canada, Athens, Georgia, U.S.A. and Pullman, Washington,
U.S.A. In Australia, business is conducted from two sites: Sydney, New
South Wales, where sales and marketing, customer support and technical
service are located; and Armidale, New South Wales, where research,
development and manufacturing facilities are located.
For more information, please visit www.Bioniche.com.
Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current
expectation regarding future events. These forward-looking statements
involve risk and uncertainties, which may cause, but are not limited
to, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact
of competitive products and pricing, new product development,
uncertainties related to the regulatory approval process, and other
risks detailed from time to time in the Company's ongoing quarterly and
SOURCE: Bioniche Life Sciences Inc.
For further information:
Jennifer Shea, Vice-President, Communications, Investor & Government Relations
Bioniche Life Sciences Inc.
Telephone: (613) 966-8058; from Australia: 0011 1 613-966-8058
Cell: (613) 391-2097; from Australia: 0011 1 613-391-2097